The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 10, 2020

Filed:

Mar. 25, 2016
Applicant:

Osi Pharmaceuticals Llc, Northbrook, IL (US);

Inventors:

Stanley C. Gill, Boulder, CO (US);

Kenneth K. Iwata, Northbrook, IL (US);

Gregory J. Riely, New York, NY (US);

Jun Wu, Buffalo Grove, IL (US);

Helena Yu, New York, NY (US);

Assignee:

OSI Pharmaceuticals, LLC, Northbrook, IL (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/517 (2006.01); A61K 45/06 (2006.01); A61K 9/51 (2006.01);
U.S. Cl.
CPC ...
A61K 31/517 (2013.01); A61K 9/5161 (2013.01); A61K 45/06 (2013.01);
Abstract

A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein.


Find Patent Forward Citations

Loading…